Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018
As reported, RX-P2382 demonstrated strong in vitro activity against all ESKAPE pathogens tested, including extremely-drug- and multidrug-resistant isolates of Escherichia coli (MIC90 0.25-0.5 μg/mL), Klebsiella pneumoniae (0.125-1 μg/mL), Pseudomonas aeruginosa (2-8 μg/mL) and Acinetobacter baumannii (0.5-2 μg/mL); vancomycin-resistant Enterococci (0.06-1 μg/mL) and Staphylococcus aureus (0.06-1 μg/mL); ciprofloxacin-resistant Neisseria gonorrhoeae (0.03-0.25 μg/mL); and carbapenem-resistant Enterobacteriaceae (0.25-2 μg/mL). In addition, RX-P2382 demonstrated efficacy in murine models of infection, including kidney, skin and respiratory infections - as well as peritonitis - caused by S. aureus, K. pneumoniae, S. pneumoniae and E. coli.
“These results, albeit early stage, support the continued development of compounds in the pyrrolocytosine class,” said
Abstracts of the presentations may be found on the ECCMID website and posters will be available on Melinta’s Publications webpage after the conclusion of the Congress’ embargo period. Melinta’s RX-P2382 presentations at ECCMID were as follows:
- Paper Poster Session (PS006) -
Progressin the ESKAPE Pathogen Program: the in vitro profile of an advanced lead, RX-P2382. 4/21/2018 3:30 - 4:30pm
- Paper Poster Session (PS009) -
Progressin the ESKAPE Pathogen Program: the exploratory in vivo toxicological profile of an advanced lead, RX-P2382. 4/21/2018 3:30 - 4:30pm
- Oral Session (OS046) -
Progressin the ESKAPE Pathogen Program: the in vivo profile of an advanced lead, RX-P2382. 4/21/2018 4:54 - 5:04pm
About the ESKAPE Pathogen Program
Melinta’s ESKAPE pathogen program is built on the Company’s technology platform based on Nobel laureate science developed at
About Melinta Therapeutics
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this communication constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control.
Risks and uncertainties for Melinta include, but are not limited to: the fact that we have incurred significant operating losses since inception and will incur continued losses for the foreseeable future; our limited operating history; our need for future capital; uncertainties of cash flows and inability to meet working capital needs as well as other milestone, royalty and payment obligations; the fact that our independent registered public accounting firm’s report on the Company’s 2016 and 2017 financial statements contains an explanatory paragraph that states that the our recurring losses from operations and our need to obtain additional capital raises substantial doubt about our ability to continue as a going concern; our substantial indebtedness; risks related to our commercial launches of our products and our inexperience as a company in marketing drug products; the degree of market acceptance of our products among physicians, patients, health care payors and the medical community; the pricing we are able to achieve for our products; failure to obtain and sustain an adequate level of reimbursement for our products by third-party payors; inaccuracies in our estimates of the market for and commercialization potential of our products; failure to maintain optimal inventory levels to meet commercial demand for any of our products; risks that our competitors are able to develop and market products that are preferred over our products; our dependence upon third parties for the manufacture and supply of our marketed products; failure to achieve the benefits of our recently completed transactions with Cempra and The
Other risks and uncertainties are more fully described in our Annual Report on Form 10-K for the year ended December 31, 2017, and in other filings that Melinta makes and will make with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made in this press release speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date after the date stated herein.
For More Information:
Source: Melinta Therapeutics